Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-06-04
Klinger Shannon Thyme Files Moderna (MRNA) Form 4 - June 04, 2026
Klinger Shannon Thyme traded 24.4K MRNA shares worth $575.3K in this Form 4 filing, reported to the SEC on 2026-06-04.
- Insider
- Klinger Shannon Thyme
- Issuer
- Moderna Inc. MRNA · NASDAQ
- Filed
- Period
- 2026-06-04
- Accession
- 0001682852-26-000119
- Source
- Official filing on sec.gov ↗
Transactions (4)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Klinger Shannon Thyme | 2026-06-05 | Buy | 11.8K | - | $0.00 | Direct |
| Klinger Shannon Thyme | 2026-06-05 | Sell | 5.7K | $51.59 | $294.3K | Direct |
| Klinger Shannon Thyme | 2026-06-04 | Buy | 3.5K | $30.96 | $107.5K | Direct |
| Klinger Shannon Thyme | 2026-06-04 | Sell | 3.5K | $50.00 | $173.6K | Direct |
| Net change | +6.1K | −$360.4K | ||||
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Track MRNA insider activity
Get alerted when Moderna Inc. executives buy or sell their shares.